China Inc. Eyes Gene Therapy In Post-Coronavirus Growth Trajectory
Large Patient Pool An Advantage?
Executive Summary
Eyeing a largely untapped treatment area and huge patient pool, biotechs in China are leaping into the gene therapy foray despite the lack of a distinct regulatory pathway or reimbursement of the highly costly treatments.